Quick Answer
VIEMED HEALTHCARE, INC. reported R&D Expense of $3.02 million for fiscal year 2025.
VIEMED HEALTHCARE, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $3.02M | -1.7% |
| 2024 | $3.07M | +10.3% |
| 2023 | $2.78M | +3.2% |
| 2022 | $2.70M | +27.8% |
| 2021 | $2.11M | +94.8% |
| 2020 | $1.08M | +27.7% |
| 2019 | $848.0K | — |
| 2018 | $0.00 | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $775.0K | +2.4% | -8.5% |
| June 30, 2025 | $847.0K | +11.7% | +6.3% |
| March 31, 2025 | $797.0K | +6.3% | +5.3% |
| September 30, 2024 | $757.0K | +27.7% | -0.1% |
| June 30, 2024 | $758.0K | +0.0% | +1.1% |
| March 31, 2024 | $750.0K | -3.8% | +26.5% |
| September 30, 2023 | $593.0K | -11.5% | -21.8% |
| June 30, 2023 | $758.0K | +12.8% | -2.8% |
- VIEMED HEALTHCARE, INC. showed a decrease of -1.7% in R&D Expense compared to the prior fiscal year.
- The most recent figure is from VIEMED HEALTHCARE, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: